» Articles » PMID: 26617663

Virological Outcome Among HIV-1 Infected Patients on First-line Antiretroviral Treatment in Semi-rural HIV Clinics in Togo

Abstract

Background: Access to antiretroviral treatment (ART) in resource-limited countries has increased significantly but scaling-up ART into semi-rural and rural areas is more recent. Information on treatment outcome in such areas is still very limited notably due to additional difficulties to manage ART in these areas.

Results: 387 HIV-1 infected adults (≥18 years) were consecutively enrolled when attending healthcare services for their routine medical visit at 12 or 24 months on first-line ART in five HIV care centers (four semi-rural and one rural). Among them, 102 patients were on first-line ART for 12 ± 2 months (M12) and 285 for 24 ± 2 months (M24). Virological failure was observed in 70 (18.1 %) patients ranging from 13.9 to 31.6 % at M12 and from 8.1 to 22.4 % at M24 across the different sites. For 67/70 patients, sequencing was successful and drug resistance mutations were observed in 65 (97 %). The global prevalence of drug resistance in the study population was thus at least 16.8 % (65/387). Moreover, 32 (8.3 %) and 27 (6.9 %) patients were either on a completely ineffective ART regime or with only a single drug active. Several patients accumulated high numbers of mutations and developed also cross-resistance to abacavir, didanosine or the new NNRTI drugs like etravirine and rilpivirine.

Conclusion: The observations on ART treatment outcome from ART clinics in semi-rural areas are close to previous observations in Lomé, the capital city suggesting that national ART-programme management plays a role in treatment outcome.

Citing Articles

Virologic Failure and Human Immunodeficiency Virus Drug Resistance in Rural Cameroon With Regard to the UNAIDS 90-90-90 Treatment Targets.

Boulle C, Guichet E, Kouanfack C, Aghokeng A, Onambany B, Ikaka C Open Forum Infect Dis. 2016; 3(4):ofw233.

PMID: 28018931 PMC: 5170495. DOI: 10.1093/ofid/ofw233.

References
1.
Gilks C, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y . The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet. 2006; 368(9534):505-10. DOI: 10.1016/S0140-6736(06)69158-7. View

2.
Fofana D, Soulie C, Balde A, Lambert-Niclot S, Sylla M, Ait-Arkoub Z . High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali. J Antimicrob Chemother. 2014; 69(9):2531-5. DOI: 10.1093/jac/dku153. View

3.
Barth R, Tempelman H, Moraba R, Hoepelman A . Long-Term Outcome of an HIV-Treatment Programme in Rural Africa: Viral Suppression despite Early Mortality. AIDS Res Treat. 2011; 2011:434375. PMC: 3065919. DOI: 10.1155/2011/434375. View

4.
Wallis C, Aga E, Ribaudo H, Saravanan S, Norton M, Stevens W . Drug susceptibility and resistance mutations after first-line failure in resource limited settings. Clin Infect Dis. 2014; 59(5):706-15. PMC: 4148601. DOI: 10.1093/cid/ciu314. View

5.
Rusine J, Asiimwe-Kateera B, van de Wijgert J, Boer K, Mukantwali E, Karita E . Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda. PLoS One. 2013; 8(8):e64345. PMC: 3741294. DOI: 10.1371/journal.pone.0064345. View